Filtros de búsqueda

Lista de obras de

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

artículo científico publicado en 2006

Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

artículo científico publicado en 2010

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

artículo científico

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

artículo científico publicado en 2014

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

artículo científico publicado en 2008

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2004

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

artículo científico publicado en 2007

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda